The measurement of plasma levels of human follicle-stimulating hormone (FSH) has proved to be of value for the study of the hypothalamic-hypophyseal-gonadal axis, greatly facilitating the diagnosis and management of problems relating to the menopause and infertility. In the present work a solid-phase radioimmunoassay for human FSH has been developed. This system is characterised by high precision, is economical, and is considerably faster to operate than conventional double antibody systems used in the hospital assay service. Reference values for plasma FSH in various endocrine states are recorded and discussed.
Materials

ANTISERUM AND HORMONE PREPARATIONS
Rabbit anti-HP-FSH serum M93 6873 was kindly provided by Professor W. R. Butt, The Birmingham and Midland Hospital for Women. Human pituitary FSH 69-104 reference preparation (Bangham et al., 1973) was also donated by Professor Butt. Human luteinising hormone HP-LH-68-40 reference standard (2nd International Reference Preparation (IRP)) and human thyroid stimulating hormone HP-TSH-68-38 (lst IRP) (Bangham and Cotes, 1971) were obtained from the National Institute for BiologicalStandards and Control, Holly Hill, Hampstead. For HCG studies the human chorionic gonadotrophin source used was Pregnyl standardised against the 2nd IS of HCG (Bangham and Cotes, 1971) from Organon, Holland.
Label Na 125 1, code IMS 30 (lOO mCi/ml) from the Radiochemical Centre, Amersham. Standards FSH-69-104 is dissolved in phosphate buffer to give a strength of 80 IU/l. This is aliquoted into 1 ml quantities and stored at -15°C. From this the following range of standards are prepared on the day of the assay: 50, 20, 10, 5, 2,5, 0'5, and 0·25 IU/l. A hormone blank is also included. Equipment Disposable LP3 polystyrene assay tubes (64 x 10mm) from Luckham Ltd, Burgess Hill, Sussex; Nuclear Chicago automated gamma counter 4218 (Illinois, USA); centrifuge MSE Minor (MSE Scientific Instruments, Crawley, Sussex); Terumo micro syringes (Shandon Ltd, Camberley, Surrey); Lumix automatic dispenser (Chemlab Ltd, Hornchurch, Essex); Gilson Pipettman dispensers (Anachem Ltd, Luton, Beds).
Assay procedure TUBE COATING Assay tubes are coated with 2 ml aliquots of HP-FSH antiserum diluted 1: 15000 in carbonate/ bicarbonate buffer, pH 10, the solution being stable in the glass Lumix dispenser. The tubes are incubated at 20°for 24 hours and aspirated, the antiserum is collected for re-use, the tubes are washed three times with pH 10 buffer, and 2 m14% BSA solution is added. After 15 minutes at 20°the tubes are aspirated, washed three times with buffer, centrifuged at 1000 rpm for 5 minutes, and aspirated to remove residual buffer. The coated tubes are stoppered and stored at 4°. To estimate the optimal antiserum dilution, a series of tubes with dilutions of antiserum from 1:10 4 to 1 :10 6 is used. The assay procedure as detailed below is then followed, and the percentage of hormone bound is calculated for each dilution.
RADIOACTIVE FSH
FSH-lz51 is prepared from FSH 69/104 by the method of Greenwood et al. (1963) , followed by further purification using Sephadex chromatography (Saxena et al., 1968) .
The specific activity of the product varies from 80 to 100~Ci/~g. It is stored at -15°C in phosphate buffer, pH 7'4. Before assay this is diluted in phosphate buffer to give about 2000 counts/min/ul, RADIOIMMUNOASSA Y Each coated tube contains:
Reconstituted NHP 50~l (for standards only) Test/Standard 100~l Buffer pH 7,4, 1800~l for standards, 1850 ul for tests Label 50~l Additions are carried out using Terumo micro syringes for volumes of 50-100 ul, and Gilson Pipettmans for volumes of 1800-1850 ul, Total radioactivity counts are measured, including carrier tubes and antibody blanks for checks on nonspecific binding. All test samples and standards are measured in triplicate. Tubes are capped, mixed on a Vortex mixer, and incubated at 20°for 24 hours. The contents are aspirated out, and the tubes are washed three times with buffer, pH 7'4, and counted for radioactivity. Standard curves are plotted (bound counts/min versus logarithm of hormone concentration) and test results are read against these. The entire assay is completed the day after being set up. For cross-reaction studies TSH, LH, and HCG replace FSH in the standards.
Performance of final procedure NON-SPECIFIC BINDING OF PLASMA
The effect of this was measured in each assay by the use of antiserum blanks.
RECOVERY STUDIES
In order to assess the accuracy of the method, different amounts of FSH were added to a plasma sample with a low level of endogenous hormone. Mean recoveries were then estimated together with respective standard deviations.
PRECISION STUDIES
Between-assay variation was assessed from assay at intervals of aliquots of three pooled plasma kept at -15 0 • The coefficients of variation were calculated for this study and also for within-assay precision as estimated by analysing triplicate assays for 330 plasma samples covering many assays.
COMPARISON WITH DOUBLE ANTIBODY METHOD
Three hundred and thirty different plasma samples with widely varying FSH content were assayed by one operator using the solid phase method and by another operator using the conventional doubleantibody method (Midgley, 1967) . Both assays used the same antiserum MR 93 6873 and the same FSH preparation MR 69-104.
COMPARISON WITH EXTERNAL QUALITY
CONTROLS
As a further check on the accuracy of the solid phase assay, external quality control samples from the World Health Organisation quality control scheme were analysed periodically, and the results were contrasted with the WHO mean assay figures, obtained by interlaboratory comparison of results from centres within the scheme.
Results
OPTIMISATION OF FACTORS
Selection of antiserum dilution
The effect of antiserum dilution was initially estimated in the absence of NHP. Under these conditions an antiserum dilution of 1 :20 000 gave a maximum binding of 30 %. Variation in incubation times had little effect on the degree of binding; 24 hours at 20 0 was considered adequate. Low temperature incubation resulted in a lowering of the percentage bound. The whole procedure was then repeated using NHP in the reaction buffer, the amount of NHP used being calculated as indicated below. When this was done the antiserum dilution corresponding to 30 %maximum binding was found to be 1: 15000 ( Fig. 1 ).
Selection of NHP dilution for standards
Freeze-dried pooled NHP was made up into solution at the strength suggested by Dade Ltd (1 mI/ ampoule). This material did not significantly vary between batches. It was then necessary to calculate the exact volume of this solution to be used in the standards so that the total inhibition due to plasma factors and hormone content was equivalent to the mean inhibition of the test samples.
Nine test samples were assayed in triplicate using the hospital routine double antibody method. A graph was constructed of counts/min observed for these samples in the solid phase assay conditions versus the logarithm of FSH values from the routine method. Sample counts/min for FSH values 0'5,2,5, 10, and 20 IU/I were estimated from curve A (Fig. 2 ). In the same solid phase assay a series of standards were run with volumes of NHP solution 
. "0" " -, :., """', of 50, 100, and 200 Ill. Graphs of NHP volume versus standard counts/min were drawn for each FSH concentration ( Fig. 3 ). From each curve the intercepts of sample counts/min for a given FSH value gave the amount of NHP required for the standards in the solid phase assay.The mean value was found to be 41 ±2 III (mean ± standard deviation). This figure is in agreement with calculations based on a comparison with the slopes of the graphs in Figure 2 . By using 1220 III water instead of 1 ml to dissolve the freeze-dried material, the volume of NHP solution to be used in the standards became 50 Ill, a convenient quantity to dispense.
., ., ., The mean percentage of bound counts in the antibody blank was 2·9 ± 2·6 (SD). Mean recoveries (±SD) for the introduction of 5, 10, 20, and 30 IU/I FSH to a plasma sample of less than 0'25 IU/I hormone concentration were 4'9 ± 0'4, 9·8 ± 0'8, 19·2 ± 1,0, and 28'3 ± 1·5 IV/I. Coefficients of variation for inter-assay variation were 6·7 (5'0), 5·0 (10'2), and 4·9 (21'3), the figures in parentheses being the mean concentrations for each plasma pool. Within-assay CVs for the solid phase and the double antibody method applied to the same 330 plasma triplicates were 5·5 and 5·8% respectively, there being little difference at various concentration ranges in this group. In Table 1 the CVs between the two methods are given. A typical standard curve is shown in Fig. 4 , where the radioactivity of FSH-1251 bound to solid phase antibody is plotted against the logarithm of the amount of hormone present. The average total count inserted into the tubes was 112000 counts/min/tube, giving a mean percentage maximum binding in the zero tube of 31'2 %. Linearity is good over the range 2'5-50 IU/l, and the working range of the assay extends to the 0·25-2'5 IU/l region. In Table 3 reference values for various endocrine states are presented from results of triplicate assays of 330 different plasma samples. Cross-reactivity of related glycoprotein hormones is slight. In terms of units of the respective MRC standards, 17 IU/I of LH, or 50 IU/I of HCG, were needed to give the same reduction in per cent bound as 0·25 IU/I of FSH. The cross-reaction of TSH was insignificant.
In Table 2 the results of quality control estimations are presented along with the mean figures given by the World Health Organisation for the centres participating in the QC scheme.
Solid phase analysis
The results presented clearly show that FSH antiserum M93 6873 has excellent characteristics for solid phase assay development. The aim of this research programme was to set up a solid phase radioimmunoassay that was both fast in operation and of high accuracy and precision. In gonadotrophin assays sensitivity is optimal at relatively low binding; for example, in the radioimmunoassay of TSH best assay sensitivity is observed using large amounts of tracer under conditions in which less than 10 % of tracer is bound (Wide et al., 1973) , although, more recently (Lemarchand-Beraud, 1975) , binding ranges of 30-50 % have been advocated for TSH assay with the proviso that cross-reaction between related glycoprotein hormones is minimised. The hormone binding curves for the FSH solid phase assay described here show that crossreaction with LH, HCG, and TSH is very low. The faint cross-reaction of TSH is probably due to the presence of LH impurities in the preparation.
A 30 % maximum binding was accordingly selected for the antiserum dilution estimation, and this proved to be satisfactory. => agreement with those reported elsewhere Korenman, 1973, 1974) . Figure 6 shows the results from determinations of FSH in plasma from 15 menstrual cycles. The cycles are synchronised around the day of the mid-cycle peak (day 0). The geometric means and the standard deviation curves are given. In the follicular phase, FSH values are generally higher than those in the luteal phase, and the general pattern of FSH secretion during the menstrual cycle follows that given by Wide et af. (1973) . The effect of age upon normal production of FSH in women is given in Figure 5 . The mean and REFERENCE VALUES Goldenberg et al. (1973) has pointed out that it is necessary to establish a normal range of values from a specific laboratory before using FSH values for diagnostic purposes and to use appropriate quality control procedures, since the normal range for FSH values appears to depend on the antiserum used, with the result that a large interlaboratory variation in plasma FSH has been reported. Reference values for normal and some endocrine states of infertility are therefore presented in this paper.
The reference values for plasma FSH measured by the solid phase method for normal women during the menstrual cycle (Table 3) , are in good One of the problems relating to radioimmunoassay measurement of hormones in plasma and serum is that human blood proteins affect the binding of gonadotrophins to antibody, necessitating the addition of a suitable gonadotrophin-free protein preparation to the standard tubes (Golstein and Vanhaelst, 1973) . One method of surmounting this difficulty in polypeptide assays would be to include pooled human plasma of negligible gonadotrophin content (Wood et al., 1975) . However, the use of such pooled plasma for incorporation into standards presents problems regarding inter-batch variation. To minimise this, purified animal protein preparations such as BSA (Amoss and Guillemin, 1968) have been used for the estimation of animal gonadotrophins. In the present work a commercially available human plasma preparation made under carefully standardised conditions was found to be satisfactory for use in the standards.
A number of trial experiments were carried out using a two-step incubation method (incubation of reactants in the absence of tracer, followed by a second incubation with the label); it was found, however, that linearity of the standard curves was improved by a one-stage (all-in) direct competitive incubation. This also had the desirable advantage of cutting down the total assay time. Indeed, the method offers an attractive alternative to the conventional radioimmunoassays since, despite the rapidity of the entire assay (completion on the following day), the within-assay precision is high, and independent checks for external quality control are excellent. In addition, the assay uses reagents that are cheap and readily available. Because of the geometry of the standard curve the working range of the assay is wide and hormone concentrations down to 0·25 IU/l are readily detectable. The method is therefore quite suitable for routine hospital assay of FSH in plasma. standard deviation curves clearly show the dramatic increase in hormonal activity as the perimenopausal state is reached at about the age of 45, the total FSH concentration and the fluctuations in the hormone levels being greatest at this point. In older women, the differences in FSH concentration become less (standard deviation curves come closer together) and the mean hormone level begins to fall. Wide et al.(1973) have studiedFSH concentrations in women up to the age of 75 and found that after the age of 60 hormone levels are significantly lower than those between 51 and 60 years of age. In the present work FSH levels in the age group 20-30 remained steady, but after the age of 30 those levels rose significantly.
FSH estimations are important in the diagnosis of the presence or absence of follicles in women (Goldenberget al., 1973) with either primary or secondary amenorrhoea. Plasma levels of FSH above the normal range for premenopausal women are indicative of the absence of follicles. Conversely, when no exogenous steroid hormones have been given and there is no evidence of pituitary disease, FSH values within the normal range are indicative of the presence of ovarian follicles. Thus surgical procedures to obtain this information should rarely be necessary.
In men, FSH secretion is related to spermatogenesis, and loss of spermatogenic activity results in an increase in plasma FSH levels (Snyder et al., 1975) . In agreement with this, the mean values for infertile males in Table 3 are twice those for the normal range. Measurement of plasma FSH levels in problems of male infertility is therefore a most useful aid. Table 3 shows that values for post-pill amenorroea are raised in contrast with normal values. Such patients do not show the normal pre-ovulatory surge of LH and have low oestrogen levels, probably due to a failure by the hypothalamus to secrete gonadotrophin-releasing hormone. Indeed, levels of FSH are known to be abnormal in patients who are post-pill amenorrhoeic, and end-organ resistance may be an important factor (Editorial, 1972) .
Hirsutism is associated with abnormal androgen levels and may be seen in patients with ovarian disorders. In polycystic ovarian disease, mean serum FSH concentrations are known to be remarkably constant and comparable to levels of FSH during the late follicular phase of the menstrual cycle (Yen et al., 1970) . In three patients with monocystic ovary syndrome FSH values have been found to be in the same range as those in the early follicular phase, and it has been proposed (Delahunt et al., 1975) that such cysts may produce abnormal amounts of ovarian steroids which modify the pituitary response. In the group of 15 hirsute women studied in the present work, the mean FSH value is depressed compared with the normal follicular phase, indicating an alteration in the pituitary response as suggested for monocystic ovary syndrome.
